A Multi‑Modal National Assessment of Linezolid‑Associated Serotonin Syndrome
5:00 PM - 6:30 PM ET
2.58 - OR FRS - A Multi‑Modal National Assessment of Linezolid‑Associated Serotonin Syndrome
Location: Plaza Ballroom D-H
First Author: Bettina Teng, MD – University of Miami/HCA JFK Hospital
Pharmacokinetics/Pharmacodynamics
5:00 PM - 6:30 PM ET
A Novel Automated Metric and Dashboard to Quantify Frequency of Antimicrobial Stewardship Interventions Across a Multicampus Health System in New England
5:00 PM - 6:30 PM ET
1.54 - OR FRS - A Novel Automated Metric and Dashboard to Quantify Frequency of Antimicrobial Stewardship Interventions Across a Multicampus Health System in New England
A Pooled Performance Analysis of ASTar® Rapid Antimicrobial Susceptibility Testing System from Pseudomonas aeruginosa Positive and Contrived Blood Cultures
5:00 PM - 6:30 PM ET
12.169 - OR - A Pooled Performance Analysis of ASTar® Rapid Antimicrobial Susceptibility Testing System from Pseudomonas aeruginosa Positive and Contrived Blood Cultures
A Retrospective Evaluation of Echinocandin Use and Discharge Feasibility
5:00 PM - 6:30 PM ET
6.123 - OR FRS - A Retrospective Evaluation of Echinocandin Use and Discharge Feasibility
Location: Plaza Ballroom D-H
First Author: Mei Li, PharmD – Massachusetts General Hospital
Fungal
5:00 PM - 6:30 PM ET
A Retrospective Study on Antibiotic Use in Dental Clinics
5:00 PM - 6:30 PM ET
1.36 - OR FRS - A Retrospective Study on Antibiotic Use in Dental Clinics
Location: Plaza Ballroom D-H
First Author: Ethan Akers, n/a – Ferris State University College of Pharmacy
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
5:00 PM - 6:30 PM ET
4.92 - E - Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
Alright, STOP, Collaborate, and Listen - Comparing Duration of Antibiotic Therapy for Gram Negative Bacteremia Between an Academic Medical Center and a Community Teaching Hospital
5:00 PM - 6:30 PM ET
1.9 - OR FRS - Alright, STOP, Collaborate, and Listen - Comparing Duration of Antibiotic Therapy for Gram Negative Bacteremia Between an Academic Medical Center and a Community Teaching Hospital
Location: Plaza Ballroom D-H
First Author: Beth Cady, PharmD – Southern Illinois University Edwardsville School of Pharmacy
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
ANALYZING URINARY TRACT INFECTIONS (UTI) AND FLUOROQUINOLONE USE WITH THE COLLABORATION TO HARMONIZE ANTIMICROBIAL REGISTRY MEASURES (CHARM)
5:00 PM - 6:30 PM ET
1.26 - OR FRS - ANALYZING URINARY TRACT INFECTIONS (UTI) AND FLUOROQUINOLONE USE WITH THE COLLABORATION TO HARMONIZE ANTIMICROBIAL REGISTRY MEASURES (CHARM)
Location: Plaza Ballroom D-H
First Author: Jonathan Guerin, n/a – Ferris State University - College of Pharmacy
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
Antibiotic Selection and Escalation in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in Tertiary Community Teaching Hospital: A Retrospective Study
5:00 PM - 6:30 PM ET
4.94 - OR FRS - Antibiotic Selection and Escalation in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in Tertiary Community Teaching Hospital: A Retrospective Study
Location: Plaza Ballroom D-H
First Author: Kuan Yu Chen, PharmD – UnityPoint Health - Iowa Methodist Medical Center
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Antibiotic Therapy and Outcomes Associated with Outpatient Dental Infections
5:00 PM - 6:30 PM ET
4.95 - OR FRS - Antibiotic Therapy and Outcomes Associated with Outpatient Dental Infections
Assessment of early clinical impacts caused by the discontinuation of a rapid phenotypic diagnostic for gram-negative bacteremia in a multihospital health system
5:00 PM - 6:30 PM ET
1.35 - OR - Assessment of early clinical impacts caused by the discontinuation of a rapid phenotypic diagnostic for gram-negative bacteremia in a multihospital health system
Assessment of Stenotrophomonas maltophilia treatment strategies and clinical outcomes for bloodstream and respiratory infections across a diverse healthcare system
5:00 PM - 6:30 PM ET
3.71 - OR FRS - Assessment of Stenotrophomonas maltophilia treatment strategies and clinical outcomes for bloodstream and respiratory infections across a diverse healthcare system
Attenuation of Ceftazidime/Avibactam Plus Aztreonam but Preservation of Levofloxacin Activity in Pseudomonas aeruginosa–Stenotrophomonas maltophilia Co-culture Models
5:00 PM - 6:30 PM ET
1.30 - OR FRS - Attenuation of Ceftazidime/Avibactam Plus Aztreonam but Preservation of Levofloxacin Activity in Pseudomonas aeruginosa–Stenotrophomonas maltophilia Co-culture Models
Aztreonam plus Ceftazidime-Avibactam versus Cefiderocol for Metallo-Beta-Lactamase-Producing Gram-Negative Infections: A Multicenter Real-World Comparison
5:00 PM - 6:30 PM ET
4.101 - OR FRS - Aztreonam plus Ceftazidime-Avibactam versus Cefiderocol for Metallo-Beta-Lactamase-Producing Gram-Negative Infections: A Multicenter Real-World Comparison
Case Series: Description of patients receiving dual long-acting injectable (LAI) antiretroviral therapy (ART) for human immunodeficiency virus (HIV) at a Syracuse, New York Inclusive Health Clinic
5:00 PM - 6:30 PM ET
7.130 - OR FRS - Case Series: Description of patients receiving dual long-acting injectable (LAI) antiretroviral therapy (ART) for human immunodeficiency virus (HIV) at a Syracuse, New York Inclusive Health Clinic
Cefepime/Zidebactam: In vivo Assessment of Resistance Selection Using Human-Simulated Regimen in a 3-Day Neutropenic Murine Lung Infection Against Carbapenem-Resistant P. aeruginosa and A. baumannii
5:00 PM - 6:30 PM ET
11.154 - OR - Cefepime/Zidebactam: In vivo Assessment of Resistance Selection Using Human-Simulated Regimen in a 3-Day Neutropenic Murine Lung Infection Against Carbapenem-Resistant P. aeruginosa and A. baumannii
Ceftazidime-Avibactam versus MEropenem-vaborbactam for the treatment of bLoodstream infections and pneumonia due to carbapenem-resistant Enterobacterales (CAMEL)
5:00 PM - 6:30 PM ET
4.108 - OR - Ceftazidime-Avibactam versus MEropenem-vaborbactam for the treatment of bLoodstream infections and pneumonia due to carbapenem-resistant Enterobacterales (CAMEL)
Characterization of monoclonal antibody VYD2311: molecular structure and in vitro neutralisation profile against recent SARS-CoV-2 variants
5:00 PM - 6:30 PM ET
5.113 - E - Characterization of monoclonal antibody VYD2311: molecular structure and in vitro neutralisation profile against recent SARS-CoV-2 variants
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Clinical surveillance software optimizes telehealth outpatient parenteral antimicrobial therapy (Tele-OPAT) workflow for 18 small community hospitals
5:00 PM - 6:30 PM ET
13.178 - OR - Clinical surveillance software optimizes telehealth outpatient parenteral antimicrobial therapy (Tele-OPAT) workflow for 18 small community hospitals
Comparative Evaluation of Human-Simulated Regimens of Cefepime/Zidebactam and Ceftolozane/Tazobactam in a Neutropenic Murine Thigh Infection Model Caused by Multidrug-Resistant Pseudomonas aeruginosa
5:00 PM - 6:30 PM ET
11.155 - OR - Comparative Evaluation of Human-Simulated Regimens of Cefepime/Zidebactam and Ceftolozane/Tazobactam in a Neutropenic Murine Thigh Infection Model Caused by Multidrug-Resistant Pseudomonas aeruginosa
Emergence of Trimethoprim‑Sulfamethoxazole Resistance During Suppressive Therapy for MRSA LVAD Infections: A Systematic Review and Analysis
5:00 PM - 6:30 PM ET
1.11 - OR FRS - Emergence of Trimethoprim‑Sulfamethoxazole Resistance During Suppressive Therapy for MRSA LVAD Infections: A Systematic Review and Analysis
Location: Plaza Ballroom D-H
First Author: Bettina Teng, MD – University of Miami/HCA JFK Hospital
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
Enterococcus faecalis endocarditis biofilm characterization and an alternative compound
5:00 PM - 6:30 PM ET
3.70 - OR - Enterococcus faecalis endocarditis biofilm characterization and an alternative compound
Equity of Oral Antimicrobial Therapy in Hospitalized People with Injection-Drug Use Related Infection Who Elect for Self-directed Discharge: A Mixed-Methods Study with Pilot Intervention
5:00 PM - 6:30 PM ET
1.48 - OR FRS - Equity of Oral Antimicrobial Therapy in Hospitalized People with Injection-Drug Use Related Infection Who Elect for Self-directed Discharge: A Mixed-Methods Study with Pilot Intervention
Evaluating the Effectiveness of Michigan Antibiotic Resistance Reduction Coalition Education Programs in Diverse Middle and High School Students in Michigan
5:00 PM - 6:30 PM ET
1.38 - OR FRS - Evaluating the Effectiveness of Michigan Antibiotic Resistance Reduction Coalition Education Programs in Diverse Middle and High School Students in Michigan
Evaluating Transitions of Care Process for Patients Discharged on Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs (VA) Healthcare System
5:00 PM - 6:30 PM ET
13.171 - OR FRS - Evaluating Transitions of Care Process for Patients Discharged on Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs (VA) Healthcare System
Evaluation of daptomycin dosing strategies and clinical outcomes using an AUC-based method with Bayesian software at an academic multisite health system
5:00 PM - 6:30 PM ET
11.144 - RIP FRS - Evaluation of daptomycin dosing strategies and clinical outcomes using an AUC-based method with Bayesian software at an academic multisite health system
Location: Plaza Ballroom D-H
First Author: Ameya Phadnis, PharmD – M Health Fairview University of Minnesota Medical Center
Pharmacokinetics/Pharmacodynamics
5:00 PM - 6:30 PM ET
Evaluation of Formulary Restriction Criteria for Cefiderocol at a Large Academic Medical Center
5:00 PM - 6:30 PM ET
1.45 - OR - Evaluation of Formulary Restriction Criteria for Cefiderocol at a Large Academic Medical Center
Evaluation of Quality of Care in Community Acquired Pneumonia in Non-Intensive Care Unit Patients at Veterans Affairs – San Diego Healthcare System
5:00 PM - 6:30 PM ET
4.88 - RIP FRS - Evaluation of Quality of Care in Community Acquired Pneumonia in Non-Intensive Care Unit Patients at Veterans Affairs – San Diego Healthcare System
Fluoroquinolones/Sulfamethoxazole-Trimethoprim vs Oral Beta-Lactams in Renal Transplant Pyelonephritis: A Retrospective Cohort Study
5:00 PM - 6:30 PM ET
4.105 - OR FRS - Fluoroquinolones/Sulfamethoxazole-Trimethoprim vs Oral Beta-Lactams in Renal Transplant Pyelonephritis: A Retrospective Cohort Study
Location: Plaza Ballroom D-H
First Author: Rebecca M. O'Toole, PharmD – University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Guardians of the Gut: Outcomes of Withholding Anti-Clostridioides difficile Therapy in Colonized Patients Following Microbiology Nudge Implementation
5:00 PM - 6:30 PM ET
4.84 - OR FRS - Guardians of the Gut: Outcomes of Withholding Anti-Clostridioides difficile Therapy in Colonized Patients Following Microbiology Nudge Implementation
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Hospital Admissions for Catheter-Related Bloodstream Infections in Dialysis Patients Without Established Outpatient Dialysis Care: Clinical Burden and Potential Impact of Taurolidine/Heparin
5:00 PM - 6:30 PM ET
10.140 - OR - Hospital Admissions for Catheter-Related Bloodstream Infections in Dialysis Patients Without Established Outpatient Dialysis Care: Clinical Burden and Potential Impact of Taurolidine/Heparin
Impact of a Pharmacist Led IV-to-PO Conversion Protocol on Length of Stay and Cost Outcomes
5:00 PM - 6:30 PM ET
1.2 - OR - Impact of a Pharmacist Led IV-to-PO Conversion Protocol on Length of Stay and Cost Outcomes
Location: Plaza Ballroom D-H
First Author: Ahmed Zaki, PharmD – Memorial Hermann Greater Heights Hospital
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
Impact of a Pharmacist-Drive Methicillin-Resistant Staphylococcus aureus Screen on Vancomycin Therapy in Children
5:00 PM - 6:30 PM ET
9.136 - OR - Impact of a Pharmacist-Drive Methicillin-Resistant Staphylococcus aureus Screen on Vancomycin Therapy in Children
Location: Plaza Ballroom D-H
First Author: Laura Bio, PharmD – Lucile Packard Children's Hospital Stanford
Pediatrics
5:00 PM - 6:30 PM ET
Impact of an Electronic Health Record alert on the number of BioFire® meningitis/encephalitis panels ordered in a large health system
5:00 PM - 6:30 PM ET
12.159 - RIP FRS - Impact of an Electronic Health Record alert on the number of BioFire® meningitis/encephalitis panels ordered in a large health system
Impact of an interdisciplinary workgroup on durations of empiric antibiotic therapy and clinical outcomes for pediatric patients with fever and chemotherapy-induced neutropenia
5:00 PM - 6:30 PM ET
1.31 - OR FRS - Impact of an interdisciplinary workgroup on durations of empiric antibiotic therapy and clinical outcomes for pediatric patients with fever and chemotherapy-induced neutropenia
Location: Plaza Ballroom D-H
First Author: Kelly Gaebel, PharmD – University of North Carolina Medical Center
Antimicrobial Stewardship
5:00 PM - 6:30 PM ET
Impact of Antibiotic Therapy on Weight in Adult Patients
5:00 PM - 6:30 PM ET
4.100 - OR FRS - Impact of Antibiotic Therapy on Weight in Adult Patients
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Impact of Rapid Blood Culture Identification (BCID2) on Time Targeted Antifungal Therapy in Patients with Fungemia: A Pre/Post Retrospective Evaluation
5:00 PM - 6:30 PM ET
12.166 - OR - Impact of Rapid Blood Culture Identification (BCID2) on Time Targeted Antifungal Therapy in Patients with Fungemia: A Pre/Post Retrospective Evaluation
Impact of Rapid Phenotypic Antimicrobial Susceptibility Testing on Antimicrobial Therapy in Patients with E. coli and K. pneumoniae Bloodstream Infections
5:00 PM - 6:30 PM ET
12.167 - OR - Impact of Rapid Phenotypic Antimicrobial Susceptibility Testing on Antimicrobial Therapy in Patients with E. coli and K. pneumoniae Bloodstream Infections
Impact of Switching Between Fidaxomicin and Vancomycin on Clinical Outcomes in Clostridioides difficile Infection: A Retrospective Cohort Study
5:00 PM - 6:30 PM ET
1.20 - OR FRS - Impact of Switching Between Fidaxomicin and Vancomycin on Clinical Outcomes in Clostridioides difficile Infection: A Retrospective Cohort Study
In Vivo Efficacy of a Human-Simulated Regimen of Cefepime/Zidebactam in a Neutropenic Mouse Lung Model of Polymicrobial Infection Caused by Carbapenem-Resistant Gram-Negative Bacteria
5:00 PM - 6:30 PM ET
11.151 - OR - In Vivo Efficacy of a Human-Simulated Regimen of Cefepime/Zidebactam in a Neutropenic Mouse Lung Model of Polymicrobial Infection Caused by Carbapenem-Resistant Gram-Negative Bacteria
Incidence of Community-Acquired Pseudomonas aeruginosa Infections in Solid Organ Transplant Recipients (SOTR) and Evaluation of Potential Risk Factors
5:00 PM - 6:30 PM ET
8.132 - RIP FRS - Incidence of Community-Acquired Pseudomonas aeruginosa Infections in Solid Organ Transplant Recipients (SOTR) and Evaluation of Potential Risk Factors
Location: Plaza Ballroom D-H
First Author: Justin Ashburn, PharmD – Department of Pharmacy, Houston Methodist Hospital
Immunocompromised
5:00 PM - 6:30 PM ET
Infectious Diseases Resident Collaboration with Care Management to Expedite Discharge for Patients Prescribed High-Risk Intravenous Antimicrobials for Outpatient Administration
5:00 PM - 6:30 PM ET
13.177 - OR FRS - Infectious Diseases Resident Collaboration with Care Management to Expedite Discharge for Patients Prescribed High-Risk Intravenous Antimicrobials for Outpatient Administration
Integrative Pharmacodynamic Modeling of Tetracycline Monotherapy and Synergistic Combinations in Stenotrophomonas maltophilia Complex
5:00 PM - 6:30 PM ET
11.152 - OR FRS - Integrative Pharmacodynamic Modeling of Tetracycline Monotherapy and Synergistic Combinations in Stenotrophomonas maltophilia Complex
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Oral Tebipenem Pivoxil vs IV Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study
5:00 PM - 6:30 PM ET
4.75 - E - Oral Tebipenem Pivoxil vs IV Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study
Outcome and experience of 2-drug regimen vs 3-drug regimen pre- and post-transition to Long-Acting Injectable Cabotegravir/Rilpvirine
5:00 PM - 6:30 PM ET
7.126 - RIP FRS - Outcome and experience of 2-drug regimen vs 3-drug regimen pre- and post-transition to Long-Acting Injectable Cabotegravir/Rilpvirine
Pharmacist Interventions at Discharge for Outpatient Parenteral Antimicrobial Therapy (OPAT): Predictors and Association with Unscheduled Healthcare Utilization
5:00 PM - 6:30 PM ET
13.176 - OR FRS - Pharmacist Interventions at Discharge for Outpatient Parenteral Antimicrobial Therapy (OPAT): Predictors and Association with Unscheduled Healthcare Utilization
Location: Plaza Ballroom D-H
First Author: Margaret Kauffeld, PharmD – M Health Fairview - University of Minnesota Medical Center
Transition of Care/Outpatient
5:00 PM - 6:30 PM ET
Pharmacist-led transitions of care intervention to address infectious disease tests pending at discharge (TPAD)
5:00 PM - 6:30 PM ET
1.19 - OR - Pharmacist-led transitions of care intervention to address infectious disease tests pending at discharge (TPAD)
Pritelivir demonstrated superior efficacy vs. investigator’s choice treatment for refractory HSV infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy results
5:00 PM - 6:30 PM ET
5.115 - E - Pritelivir demonstrated superior efficacy vs. investigator’s choice treatment for refractory HSV infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy results
Location: Plaza Ballroom D-H
First Author: Yeon Joo Lee, MD – Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
Clinical Studies/Trials
5:00 PM - 6:30 PM ET
Prolonged Infusion of Beta-lactam Antibiotics for Treating Ventriculoperitoneal Shunt-related Central Nervous System Infections in Pediatric Patients: A Case Series
5:00 PM - 6:30 PM ET
9.138 - OR FRS - Prolonged Infusion of Beta-lactam Antibiotics for Treating Ventriculoperitoneal Shunt-related Central Nervous System Infections in Pediatric Patients: A Case Series
Location: Plaza Ballroom D-H
First Author: Taylor Le, PharmD – Lucile Packard Children's Hospital Stanford
Pediatrics
5:00 PM - 6:30 PM ET
Qualitative Assessment of Antibiotic Prescribing through Physician-Pharmacist Collaboration: A Multicenter Study in Korea
5:00 PM - 6:30 PM ET
1.23 - OR - Qualitative Assessment of Antibiotic Prescribing through Physician-Pharmacist Collaboration: A Multicenter Study in Korea
Retrospective, multicenter evaluation of reflex urine culture criteria and workflow changes in emergency departments across six hospitals and three off-campus sites
5:00 PM - 6:30 PM ET
1.55 - OR FRS - Retrospective, multicenter evaluation of reflex urine culture criteria and workflow changes in emergency departments across six hospitals and three off-campus sites
Retrospective, multi-hospital evaluation of pneumococcal urinary antigen testing before and after a diagnostic stewardship educational campaign with order set updates
5:00 PM - 6:30 PM ET
1.52 - OR FRS - Retrospective, multi-hospital evaluation of pneumococcal urinary antigen testing before and after a diagnostic stewardship educational campaign with order set updates
Safety, Tolerability, Pharmacokinetics, and Immunogenicity in a Phase 1 First-in-human Study with VYD2311, a SARS-CoV-2-directed Monoclonal Antibody
5:00 PM - 6:30 PM ET
5.112 - E - Safety, Tolerability, Pharmacokinetics, and Immunogenicity in a Phase 1 First-in-human Study with VYD2311, a SARS-CoV-2-directed Monoclonal Antibody
Clinical Infectious Diseases and Use of Antimicrobials
5:00 PM - 6:30 PM ET
Target redundancy: Harnessing complementary PBP binding profile to evaluate synergy between sulbactam and cefepime/zidebactam against dual carbapenemase-producing A. baumannii
5:00 PM - 6:30 PM ET
2.63 - OR - Target redundancy: Harnessing complementary PBP binding profile to evaluate synergy between sulbactam and cefepime/zidebactam against dual carbapenemase-producing A. baumannii
Therapeutic Outcomes of Oral Antibiotics in Methicillin-Resistant Staphylococcus aureus Urinary Tract Infections: A Comparison of Linezolid, Trimethoprim–Sulfamethoxazole, and Doxycycline
5:00 PM - 6:30 PM ET
4.107 - OR FRS - Therapeutic Outcomes of Oral Antibiotics in Methicillin-Resistant Staphylococcus aureus Urinary Tract Infections: A Comparison of Linezolid, Trimethoprim–Sulfamethoxazole, and Doxycycline
Treatment strategies and clinical outcomes for patients with pneumonia and/or bloodstream infection (BSI) due to carbapenem-resistant A. baumannii (CRAB): Early insights from the TUNDRA study
5:00 PM - 6:30 PM ET
4.91 - OR - Treatment strategies and clinical outcomes for patients with pneumonia and/or bloodstream infection (BSI) due to carbapenem-resistant A. baumannii (CRAB): Early insights from the TUNDRA study